
A Feature from Patrick Branch, Partner, Tokyo Office Head, LEK Consulting.
Japan’s improving macro environment continued strength across several market segments and a dynamic deal environment gave market observers cause of encouragement in 2025, despite pedestrian top-line market growth.
The government’s efforts to catalyze ecosystem ‘takeoff’, along with a number of compelling storylines at Japan’s major pharma companies, added to the market’s dynamism.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze